Aranzazu Mateo-Garcia

Segovia, CL, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.

Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival.

Journal: British journal of haematology

Published: February 26, 2026

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Journal: Blood advances

Published: September 26, 2025

Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation.

Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 24, 2025

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease.

Journal: Annals of hematology

Published: July 24, 2024

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 22, 2024

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.

Journal: Haematologica

Published: April 23, 2024

Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.

Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.

Journal: Haematologica

Published: November 29, 2022

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

Journal: Blood cancer journal

Published: January 11, 2022

Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.

Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival.

Journal: British journal of haematology

Published: November 29, 2021

B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients.

B-Cell Regeneration Profile and Minimal Residual Disease Status in Bone Marrow of Treated Multiple Myeloma Patients.

Journal: Cancers

Published: February 08, 2021

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.

6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival.

Journal: British journal of haematology

Published: May 18, 2020

Clinical management and follow-up of relapsed immune thrombotic thrombocytopenic purpura during pregnancy: A case report.

Clinical management and follow-up of relapsed immune thrombotic thrombocytopenic purpura during pregnancy: A case report.

Journal: Thrombosis research

Published: February 26, 2020

Showing 1-12 of 17

Last Updated: 09/26/2026